Loading
A phase 3 trial of Trastuzumab pamirtecan run by DualityBio Inc., active.
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) is a phase 3 interventional study registered as NCT06018337 by DualityBio Inc., with 541 participants enrolled, started 2024-01-18. Conditions listed: Metastatic Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, Antibody-drug conjugate (ADC).
Shares Trastuzumab pamirtecan, Duality Biotherapeutics, Antibody-drug conjugate (ADC).
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, HER2-positive breast cancer, Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer.
Shares HER2-low and HER2-ultralow metastatic breast cancer, Antibody-drug conjugate (ADC), HR-positive / HER2-negative breast cancer.
Shares Trastuzumab pamirtecan, Antibody-drug conjugate (ADC).
Shares HER2-low and HER2-ultralow metastatic breast cancer, HR-positive / HER2-negative breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/